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BACKGROUND: We recently identified and validated UBE2C RNA as a prognostic marker in 252 node-positive (Nþ) breast cancers by
means of a microarray study. The aim of this study was to validate UBE2C protein as a prognostic marker in Nþ breast cancer by
immunohistochemistry (IHC).
METHODS: To this end, 92 paraffin-embedded blocks were used. The impact of UBE2C IHC value on metastasis-free survival (MFS)
and overall survival (OS) was evaluated and compared with Ki-67 and Nottingham prognostic index (NPI) performances.
RESULTS: In accordance with genomic data, UBE2C IHC had a significant impact both on MFS and OS (hazard ratio¼6.79 – P¼0.002;
hazard ratio¼7.14 – P¼0.009, respectively). Akaike information criterion proved that the prognostic power of UBE2C IHC was
stronger than that of Ki-67 (and close to that of NPI). Furthermore, multivariate analyses with NPI showed that, contrary to Ki-67
IHC, UBE2C IHC remained an independent factor, both for MFS (adjusted P¼0.02) and OS (adjusted P¼0.04).
CONCLUSION: We confirmed that UBE2C protein measured by IHC could be used as a prognostic marker in Nþ breast cancer. The
potential predictive interest of UBE2C as a marker of proteasome activity needs further investigations.
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The ubiquitin–proteasome system (UPS) is involved in many,
if not all, cellular events through the regulation of protein
homoeostasis and fate (Hershko et al, 2000). It consists of a key
protein, ubiquitin; several enzymes, ubiquitin-activating enzyme
(E1), ubiquitin-conjugating enzymes (E2), ubiquitin-ligating
enzymes (E3), deubiquitinating enzymes and a highly sophisti-
cated protease complex, the 26S proteasome. The latter is made up
of two subcomplexes: a catalytic core particle (20S proteasome:
PSMA and PSMB subunits) and one or two terminal 19S particle(s)
(PSMC and PSMD subunits), which serve as proteasome activators
(Tanaka, 2009). With the multitude of substrates targeted and the
numerous processes involved, it is not surprising that aberrations
in this pathway have been implicated in the pathogenesis of many
diseases, such as cancer and, more specifically, breast cancer
(Lipkowitz, 2002; Ohta and Fukuda, 2004; Mani and Gelman,
2005).
Proteomic and genomic studies conducted by our team pointed
out different elements of the UPS as breast cancer prognostic
markers: ubiquitin as a prognostic protein marker in node-
negative (N-) patients, and UBE2C, PSMA5, PSMB3, PSMB7, and
PSMD3 as prognostic nucleic acid markers in node-positive (Nþ)
patients, respectively (Ricolleau et al, 2006; Campone et al, 2008;
Je ´ze ´quel et al, 2008). Our results were consistent with those of
other studies (Chen and Madura, 2005; Deng et al, 2007). Of the 38
genes included in our 38-gene expression signature, UBE2C was
the most highly ranked gene. Furthermore, evaluation of the
prognostic power of this gene on external microarray data (more
than one thousand) confirmed the robustness of this marker at
the RNA level (Je ´ze ´quel et al, 2008). This finding was consistent
with reports that underlined a strong link between UBE2C
overexpression and the degree of tumour differentiation in many
cancers (breast, lung, ovary, bladder, and glioblastomas) (Okamo-
to et al, 2003; Wagner et al, 2004). Furthermore, in breast cancer,
an increased expression of UBE2C was associated with high
tumour grade and cancer progression (Ma et al, 2003). Finally,
UBE2C belongs to proliferative genes, which are known to
constitute the majority of genes included in prognostic gene-
expression signatures (Desmedt et al, 2008; Wirapati et al, 2008).
The robustness of this marker may render it suitable for routine
use, but the practicability of its measurement might be improved
by using immunohistochemistry (IHC) staining. This technique
might be preferred over nucleic acid measurement because of three
advantages. First, IHC is considered as a practical approach in
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sroutine testing because of its relative inexpensiveness and straight-
forwardness, and is well established in standard clinical pathology
laboratories. Second, IHC is applicable to paraffin-embedded
tissues; there is no need for fresh, frozen, nonfixed tissue as a
preferential requirement for nucleic acid quantification. Third, a
more likely relevant validation consists of studying the expression
level of a potential biomarker at a protein level, such as with IHC.
Studies have shown that there is often discordance between levels
of nucleic acids and proteins, implying that the study of both
measures is important.
So the aim of this study was (1) to determine the prognostic
power of UBE2C by means of IHC staining in 92 Nþ breast cancer
patients; (2) to compare the power of this proliferation marker
with that of the reference marker in breast cancer, Ki-67, and (3) to
evaluate if UBE2C added predictive accuracy to that provided by
the combined prognostic index: Nottingham Prognostic Index
(NPI) (Stuart-Harris et al, 2008).
MATERIALS AND METHODS
Patients
The study included paraffin-embedded blocks from 92 consecutive
women with primary Nþ breast tumours, who were diagnosed
and treated primarily between April 1997 and July 2001 at the Rene ´
Gauducheau Cancer Centre. Forty-three patients were also part of
a previous genomic study that led to the identification of a 38-gene
expression node-positive prognostic signature (Je ´ze ´quel et al,
2008). The median age at diagnosis was 51 years (range, 27–74
years). Informed consent was obtained from patients to use their
surgical specimens and clinicopathological data for research
purposes, as required by the French Committee for the Protection
of Human Subjects. These patients showed no evidence of distant
metastasis at the time of diagnosis. None had received chemo-
therapy, endocrine therapy or radiation therapy before surgery.
Treatment decisions were based solely on consensus recommenda-
tions at the time of diagnosis. Patients were followed up for
metastasis-free survival (MFS) (delimited by the first clinically
recognised evidence of distant recurrence). All patients received
FEC adjuvant chemotherapy and post-operative radiation
therapy. Seventy-four received hormonotherapy (tamoxifen).
Patients were followed up every 4 months during 2 years,
then every 6 months during 3 years, and annually thereafter.
Clinical examination, mammography and chest radiography
were performed twice a year, and bone scintigraphy and liver
ultrasonography annually.
IHC
Sections (3mm) from formalin-fixed, paraffin-embedded tumours
were cut and mounted on Superfrost Plus slides (VWR Interna-
tional, Leicestershire, UK). Following deparaffinisation in xylene,
slides were rehydrated through a graded series of alcohol and
placed in running water. Endogenous peroxidase activity was
blocked with 3% hydrogen peroxide and methanol. Samples were
steamed before incubation for antigen retrieval with 10mM citrate
buffer (pH 6.0) for UBE2C and EDTA pH 7.2 for Ki-67. Slides were
incubated for UBE2C (Boston Biochem, Cambridge, UK, dilution:
1/500) and Ki-67 (Dako, Glostrup, Denmark, clone MIB1, dilution:
1/100) using a biotin-streptavidin-peroxidase detection system
(Kit ChemMate, Dako). 3,30-diaminobenzidine tetrahydrochloride
(DAB) was used for the visualisation of the antibody/enzyme
complex. Slides were counterstained with haematoxylin. Negative
controls were included in each case by omitting the primary
Figure 1 Immunohistochemistry staining of UBE2C and Ki-67 in node-positive breast carcinomas. (A) High expression of UBE2C with intense nuclear
immunostaining of carcinoma cells. (B) Low expression of UBE2C with nuclear immunostaining of rare carcinoma cells. (C) High expression of Ki-67 with
strong nuclear immunostaining of carcinoma cells. (D) Low expression of Ki-67 with rare immunostained carcinoma cells.
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santibody. Ki-67 and UBE2C scores were defined as the percentage
of immunostained cells divided by the total number of cells in the
evaluated area. All counts were performed at a magnification of
 40 using a standard light microscope. The percentage of UBE2C
and Ki-67 stained cells was evaluated individually and inde-
pendently by two pathologists (DL, FL) in a double-blind manner.
For each case, 250 cells were counted.
Statistical analysis
Descriptive statistics Categorical data were presented as frequen-
cies and continuous variables were expressed as the median
(range). It was also decided not to use the best, but most likely
overfitted, cut-off for Ki-67 but the one calculated from 2685
patients by Viale et al (2008) 11% . The same one was used for
UBE2C. Relationships between UBE2C IHC groups (o11% vs
X11%) and other parameters were determined by using the non-
parametric Mann–Whitney test if continuous and Fisher’s exact
test if discrete.
Inter-observer reproducibility Agreement between pathologists
(DL and FL) for UBE2C and Ki-67 was verified in two ways: if
continuous, by means of Spearman’s correlation; if discretised
(o11% vs X11%), by means of Kappa test.
Correlation study between genomic and IHC data Microarray and
IHC data were available for 40 patients. Microarray characteristics
and data have been deposited in the NIH Gene Expression
Omnibus (Series accession number: GSE11264) according to
minimum information about a microarray experiment (MIAME)
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc¼GSE11264)
(Je ´ze ´quel et al, 2008). UBE2C RNA expression was measured by
means of the two different cDNA probes named: UMGC_02270 and
UMGC_06429. Correlation between UBE2C RNA expression and
UBE2C IHC was determined by means of Spearman’s test.
Moreover, to be able to extrapolate results concerning UBE2C
IHC impact on MFS, the previously shown prognostic value of
UBE2C genomic value on n¼252 patients was verified on this
subsample (n¼40) by univariate Cox regression. UBE2C genomic
data are detailed in Supplementary Table 1 (Je ´ze ´quel et al, 2008).
Survival analysis Categorical time from surgery to metastasis
relapse (MR) (primary end point) was retained for the study.
Overall survival (OS), defined as time from surgery to death from
any cause, was used to reinforce MFS analysis. MFS curves were
plotted according to Kaplan–Meier method and compared by
means of the log-rank test. Cox’s proportional hazard regression
analyses were performed on UBE2C and Ki-67 expression
Table 1 Clinical and pathological characteristics of node-positive breast
cancer patients
Variable All patients (n¼92)






























ER¼oestrogen receptor; IDC¼infiltrating ductal carcinoma; NPI¼Nottingham
prognostic index; PR¼progesterone receptor; SBR¼Scarff–Bloom–Richardson.
aMedian (s.d.)







a 54.5 (10.4) 0.030
Histology
IDC  61 2
IDC+ 34 40 0.301
Histological size
Raw value 25 (14) 30 (14) 0.116
o20mm 14 9




III 5 26 o0.001
Positive nodes
p33 43 2
43 6 20 0.019
ER
  21 1
+ 38 41 0.035
PR
  71 7
+ 33 35 0.150
Hormonotherapy
  61 2
+ 34 40 0.430
IHC Ki-67
o11% 25 2
X11% 15 50 o0.001
NPI
17 0
22 7 2 4
36 2 8 o0.001
ER¼oestrogen receptor; IDC¼infiltrating ductal carcinoma; IHC¼immuno-
histochemistry; NPI¼Nottingham prognostic index; PR¼progesterone receptor;
SBR¼Scarff–Bloom–Richardson.
aMean (s.d.)
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s(discretised and continuous) and on all other known prognostic
parameters to assess their independent association with MFS and
OS. Proportional hazard assumption was verified for the final
models by means of Schoenfeld residuals study. On account of the
moderate number of MR and deaths during follow-up (n¼25/92
and 18/92, respectively), permutation tests were performed both
at univariate and multivariate steps to optimise the robustness of
the results.
Comparison and independence Prognostic power for MFS and
OS was compared for UBE2C IHC and Ki-67 IHC both
discretised at retained cut-off (o11% vs X11%) and for the NPI
(classical prognostic reference) by means of Akaike information
criterion (AIC) at univariate step. At multivariate step, Cox’s
regression analysis was used to determine whether UBE2C IHC
and Ki-67 IHC (11%) added independent prognostic information
to NPI.
Sensitivity, specificity Receiver operating characteristic (ROC)
analysis with MR and death within 7 years as a defining point was
computed. The area under the curve (AUC) was used as a measure
of the marker global performance in the test set. ROC curves were
calculated for UBE2C IHC and Ki-67 IHC (11%) and the bio-
clinical prognostic index, NPI.
All data were analysed with SAS version 9.1 (SAS Institute,




The UBE2C immunostaining was observed essentially in the
nuclei of the carcinoma cells; however, in some cases, it was
associated with a cytoplasmic immunostaining. The immuno-
staining was almost always of strong intensity (Figure 1A and B).
For Ki-67 immunostaining, only nuclear staining was interpreted
as positive; the intensity varied between mild and strong
(Figure 1C and D). The patterns of UBE2C and Ki-67 immuno-
staining were similar. Exceptionally, for both Ki-67 and UBE2C,
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Figure 2 Correlation between UBE2C IHC values and UBE2C genomics
value for UMGC_2270 GEO ID probe (A) and UMGC_6429 GEO ID
probe (B).









Age 1.08 1.03–1.13 0.001 o0.001
Histology
IDC vs others 0.58 0.24–1.39 0.219 0.265
Histological size
Raw value 1.03 1.01–1.05 0.035 0.063
X20mm vs
o20mm
1.92 0.66–5.59 0.233 0.194
SBR
I vs II vs III 3.15 1.59–6.23 0.001 o0.001
SBR
I, II vs III 3.94 1.72–9.01 0.001 o0.001
N1 positive nodes 1.28 1.17–1.40 o0.001 o0.001
Positive nodes
1 vs 2 vs 3 vs 4 3 2.02 1.39–2.94 o0.001 o0.001
Positive nodes
o3 vs X3 5.17 2.30–11.64 o0.001 o0.001
ER
+ vs   0.21 0.09–0.49 o0.001 0.001
PR
+ vs   0.42 0.19–0.94 0.035 0.043
Hormonotherapy
+ vs   0.39 0.17–0.91 0.029 0.042
IHC Ki-67 raw value 1.02 1.01–1.04 0.011 0.012
IHC Ki-67
o11% vs X11% 5.69 1.34–24.2 0.018 0.002
IHC UBE2C raw
value
1.03 1.01–1.04 0.001 o0.001
IHC UBE2C
o11% vs X11% 6.79 2.03–22.73 0.002 o0.001
NPI raw value 2.81 1.84–4.28 o0.001 o0.001
NPI score
1 vs 2 vs 3 5.45 2.33–12.71 o0.001 o0.001
NPI
1, 2 vs 3 5.85 2.44–14.04 o0.001 o0.001
CI¼confidence interval; ER¼oestrogen receptor; HR¼hazard ratio; IDC¼infiltra-
ting ductal carcinoma; IHC¼immunohistochemistry; NPI¼Nottingham prognostic
index; PR¼progesterone receptor; SBR¼Scarff–Bloom–Richardson.
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swe observed nuclear immunostaining in rare normal ductal
epithelial cells.
Statistical analysis
Descriptive analysis The clinical and pathological characteristics
of the 92 patients are detailed in Table 1. UBE2C IHC high level
(X11%) was significantly related to other bad prognostic
parameters such as high SBR grade, number of positive nodes,
negative ER, high NPI and high Ki-67 IHC level (Table 2).
Inter-observer reproducibility The UBE2C and Ki-67 IHC results
are robust as they showed high inter-observer reproducibility
(Supplementary Table 1 and Supplementary Figure 1). As
continuous parameters, Spearman’s Rho showed high correlation
between both pathologists (DL and FL) for both parameters
(r¼0.977 – Po0.0001 and r¼0.951 – Po0.0001 for UBE2C and
Ki-67, respectively). When discretised (o11% vs X11%), Kappa
test also showed high agreement (k¼0.82 – Po0.0001 and
k¼0.72 – Po0.0001 for UBE2C and Ki-67, respectively).
Correlation study between genomic and IHC data Genomic and
IHC data were available for 40 patients. Microarray values of
the two UBE2C cDNA probes were significantly correlated with
UBE2C IHC values (r¼0.51 – P¼0.0009 and r¼0.65 – Po0.0001
for UMGC_2270 and UMGC_6429, respectively) (Supplementary
Table 1 and Figure 2).
Correlation study between genomic and MFS For the 40 patients
with available UBE2C microarray data, prognostic value
was confirmed for MFS prediction for both gene probes (hazard
ratio (HR)¼2.99, 95% confidence interval (CI))¼(1.48–6.06)
– P¼0.002 and HR¼2.21, 95% CI¼(1.32–3.69) – P¼0.002 for
UMGC_2270 and UMGC_6429, respectively). Prognostic value was
also confirmed for OS prediction for both UBE2C cDNA probes
(HR¼5.27, 95% CI¼(2.36–11.74) – Po0.001 and HR¼2.78, 95%
CI¼(1.62–4.76) – Po0.001 for UMGC_2270 and UMGC_6429,
respectively). As UBE2C IHC and UBE2C genomic data were
correlated, on the one hand, with each other and, on the other,
with MFS, one can suggest the use of a more practicable technique









Age 1.06 1.01–1.12 0.026 0.022
Histology
IDC vs others 0.48 0.18–1.27 0.139 0.149
Histological size
Raw value 1.02 0.99–1.05 0.133 0.157
o20mm vs
X20mm
2.97 0.68–12.94 0.147 0.090
SBR
I vs II vs III 3.97 1.67–9.47 0.001 o0.001
SBR
I, II vs III 5.93 2.08–16.89 0.001 o0.001
No positive nodes 1.28 1.15–1.42 o0.001 o0.001
Positive nodes
1 vs 2 vs 3 vs 4 3 1.81 1.19–2.74 0.005 0.002
Positive nodes
o3 vs X3 3.89 1.53–9.89 0.004 0.002
ER
+ vs   0.18 0.07–0.47 o0.001 o0.001
PR
+ vs   0.51 0.19–1.37 0.182 0.210
Hormonotherapy
+ vs   0.34 0.13–0.92 0.034 0.037
IHC Ki-67 raw value 1.03 1.01–1.05 0.001 0.005
IHC Ki-67
o11% vs X11% 8.59 1.14–64.57 0.037 0.003
IHC UBE2C raw value
1.03 1.01–1.05 o0.001 0.002
IHC UBE2C
o11% vs X11% 7.14 1.64–31.11 0.009 o0.001
NPI raw value 2.70 1.66–4.41 o0.001 o0.001
NPI scores
1 vs 2 vs 3 4.48 1.74–11.52 0.002 o0.001
NPI
1, 2 vs 3 4.74 1.77–12.69 0.002 o0.001
CI¼confidence interval; ER¼oestrogen receptor; HR¼hazard ratio; IDC¼infiltra-
ting ductal carcinoma; IHC¼immunohistochemistry; NPI¼Nottingham prognostic
index; PR¼progesterone receptor; SBR¼Scarff–Bloom–Richardson.
























52 45 35 29 23 1 ≥11% 




























65 57 47 39 27 2 ≥11%
27 26 26 25 18 2 <11%  
Number at risk
0 2 4 6 8 10
Years
Figure 3 Kaplan–Meier analysis for MFS according to UBEC (A) and
Ki-67 (B) IHC value.
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s(IHC) as a reliable way to measure the level of UBE2C and the
transfer of this analysis to clinical routine.
Comparison of parameters for prognostic evaluation
Univariate step UBE2C IHC and Ki-67 IHC were both signifi-
cantly related to MFS and OS (Tables 3 and 4; Figures 3 and 4).
Prognostic power for MFS, measured by AIC, was greater for
NPI or UBE2C IHC than for Ki-67 IHC (199.62o202.89o208.74,
respectively). Prognostic power for OS, measured by AIC, was
greater for UBE2C IHC or NPI than for Ki-67 IHC
(146.91o147.39o149.42, respectively). Moreover, ROC analysis
(MR within 7 years as a defining point) showed that AUC was 0.77,
0.74 and 0.69 for NPI, UBE2C and Ki-67, respectively (P¼0.17).
For death (7 years as a defining point), AUC was 0.74, 0.69 and 0.66
for NPI, UBE2C and Ki-67, respectively (P¼0.43). In conclusion,
univariate survival prediction’s performance of UBE2C IHC
is close to that achieved by NPI, and both are better than
Ki-67 IHC. The results of all bio-clinical parameters are listed in
Tables 3 and 4.
Multivariate step Multivariate analyses showed that, for MFS and
OS, discretised (11%) UBE2C IHC (but not Ki-67 IHC) remained
an independent factor that added prognostic information to bio-
clinical index NPI, which was the most relevant bio-clinical
parameter (Tables 5 and 6, data not shown).
DISCUSSION
In this study, we have confirmed that increased expression of
UBE2C protein was linked to poor prognosis in Nþ breast cancer.
Our result is in contradiction with Berlingieri et al (2007)
who evaluated prognostic informativity of UBE2C and found no
relation between this protein and the rates of overall and relapse-
free survival. According to the following points, we strongly
believe that UBE2C is a prognostic marker of breast cancer. First,
we previously found the same result for this marker at the RNA
level in a cohort of 252 node-positive breast cancer patients
(Campone et al, 2008; Je ´ze ´quel et al, 2008). Second, UBE2C
microarray data analysis of six other breast cancer genomic studies
gave the same result in both Nþ and N  patients (Je ´ze ´quel et al,
2008). Third, we found a significant correlation between UBE2C
genomic values and UBE2C IHC values. Finally, our IHC study
included more patients than did that of Berlingieri (92 instead
of 74).
In regard to our recent studies and other ‘Omics’ studies,
numerous components of the UPS have been found to be related to
breast carcinogenesis and an unfavourable evolution in breast
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Figure 4 Kaplan–Meier analysis for OS according to UBEC (A) and
Ki-67 (B) IHC value.
Table 5 Metastasis-free survival analyses for UBEC2C and Ki-67 adjusted










1, 2 vs 3 3.65 1.44–9.24 0.006 0.002
UBE2C IHC
o11% vs X11% 3.83 1.06–13.81 0.041 0.024
NPI
b
1, 2 vs 3 4.30 1.68–11.03 0.002 0.001
Ki-67 IHC
o11% vs X11% 2.65 0.56–12.59 0.220 0.195
CI¼confidence interval; HR¼hazard ratio; IHC¼immunohistochemistry;
NPI¼Nottingham prognostic index.
aNPI adjusted for UBE2C IHC.
bNPI adjusted for
Ki-67 IHC.
Table 6 Overall-survival analyses for UBEC2C and Ki-67 adjusted for










1, 2 vs 3 2.86 1.01–8.07 0.047 0.038
UBE2C IHC
o11% vs X11% 4.52 0.96–21.32 0.057 0.040
NPI
b
1, 2 vs 3 3.15 1.14–8.76 0.028 0.029
Ki-67 IHC
o11% vs X11% 4.98 0.61–40.56 0.133 0.074
CI¼confidence interval; HR¼hazard ratio; IHC¼immunohistochemistry;
NPI¼Nottingham prognostic index.
aNPI adjusted for UBE2C IHC.
bNPI adjusted for
Ki-67 IHC.
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scancer (Chen and Madura, 2005; Ricolleau et al, 2006; Deng et al,
2007; Campone et al, 2008; Je ´ze ´quel et al, 2008). Furthermore,
increased activity of the proteasome was directly linked to
overexpression of UPS elements (ubiquitin enzymes and protea-
somal subunits) (Chen and Madura, 2005). We can therefore
hypothesise, first, that poor prognosis in Nþ breast cancer is
related in a large part to a high activity of the UPS, itself related to
tumour high proliferative metabolism, and second, that UBE2C
might be considered as a marker of proteasome activity.
On account of the central role of proteasome in protein
homoeostasis and fate, whose dysregulation may lead to cancer,
therapeutic strategies focused on this potential target; proteasome
inhibitors could provide a new and promising class of anticancer
agents (Ciechanover, 2003; Orlowsky and Dees, 2003; Sato et al,
2008). Since the discovery of bortezomib as proteasome inhibitor,
this macromolecular protein assembly is to be considered as a
therapeutic target. This drug has been approved by the Food and
Drug Administration for treatment of relapsed and refractory
multiple myeloma. But no effect was found in breast cancer when it
was used as a single agent despite a proven efficacy when
combined with several chemotherapeutic agents (Cusak, 2003).
Two considerations may be advanced to explain this treatment
failure. First, following the example of antioestrogens and
hormone receptors, Herceptin and the HER2/neu receptor, it
seems probable that the activity of the proteasome might be
evaluated before any treatment with bortezomib (Marx et al, 2007).
We propose that proteasome activity measurement could be
determined by an indirect method: UBE2C IHC. To this end, we
will soon compare a direct method by means of a fluorigenic
substrate to UBE2C IHC (Chen and Madura, 2005). Second,
according to recent study and the disappointing results of clinical
trials using bortezomib as monotherapy in some solid tumours, it
appears that this molecule should be used in combination. In 2006,
Cardoso et al (2006) showed a synergy between bortezomib and
trastuzumab in HER2/neuþþþ/þþ cell lines. These results
convinced the authors to conduct a phase 1 clinical trial that aimed
at evaluating this drug combination.
On the basis of genomic data of a previous study, the
hierarchical cluster analysis dendrogram of the 219 genes with
the highest prognostic information in 252 Nþ breast cancer
patients showed a direct link between 2 proteasome subunit genes
located in 17q12 and ERBB2 locus, known to be a hot spot of gene
amplification in breast cancer. This cluster contains: PSMD3,
PSMB3, STARD3, C17orf37 and ERBB2 (Supplementary Figure 2)
(Je ´ze ´quel et al, 2008). Furthermore, PSMD3 and PSMB3 have been
found to be overexpressed through gene amplification of ERBB2
locus in numerous studies (Kauraniemi et al, 2003; Buness et al,
2007). The relation between ERBB2 locus amplification, protea-
some subunits overexpression and proteasome activity still needs
to be explored, but the results exposed above may let us think that
a functional link exists, and so a therapeutic approach should
strongly consider this possibility.
In conclusion, in breast cancer, any new clinical trial testing
bortezomib should compare bortezomib in combination (e.g.,
trastuzumab) vs the single molecule, and should include patients
with proteasome high activity, which could be indirectly evaluated
by UBE2C IHC staining.
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